Kelun-Biotech Announces Breakthrough Therapy Designation Granted for Sacituzumab Tirumotecan (Sac-TMT) in Combination With Tagitanlimab in China for Certain Types of Non-Small Cell Lung Cancer
CHENGDU, China, June 10, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") today announced that its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) (佳泰莱®) in combination with the PD-L1 monoclonal antibody tagitanlimab (科泰莱®) was granted Breakthrough Therapy Designation by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China for the first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) without actionable genomic alterations. Breakthrough Therapy Designation is granted for treatment options that demonstrate significant clinical advantages over currently available treatments and is aimed at expediting the research, development and marketing of innovative treatment options that address clinically urgent medical needs. This designation is based on the efficacy and safety data from the non-squamous cohort of the Phase II OptiTROP-Lung01 study.
This marks the fifth Breakthrough Therapy Designation granted to sac-TMT by the NMPA. Sac-TMT has previously received this designation for:
Locally advanced or metastatic triple-negative breast cancer (TNBC) in July 2022;
EGFR-mutant, locally advanced or metastatic NSCLC after progression on EGFR-TKI therapy in January 2023;
Locally advanced or metastatic hormone-receptor positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC) in patients who have previously received at least two lines of systemic chemotherapy in June 2023；
First-line treatment of unresectable locally advanced, recurrent or metastatic PD-L1 negative TNBC in March 2024.
Results from a Phase 2 OptiTROP-Lung01 study of sac-TMT in combination with tagitanlimab in first-line advanced or metastatic non-squamous NSCLC patients were presented in a poster session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting[1].
Dr. Michael Ge, CEO of Kelun-Biotech said, "This designation by the NMPA highlights the importance of developing novel therapeutic options for diverse NSCLC subtypes. Sac-TMT in combination with tagitanlimab demonstrated clinically meaningful outcomes in key endpoints for patients with non-squamous NSCLC without actionable genomic alterations as a first-line treatment. We are excited about the therapeutic potential of TROP2 ADC- immunotherapy combinations, and we look forward to working with regulatory authorities in China to bring this combination therapy to patients in need as soon as possible."
[1] Abstract #8529: Lung Cancer – Non-Small Cell Metastatic, ASCO Annual Meeting, 2025
About sac-TMT (佳泰莱®)Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, BC, gastric cancer (GC), gynecological tumors, among others. Sac-TMT is developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells.
In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc., Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (includes Mainland China, Hong Kong, Macao, and Taiwan).
To date, two indications for sac-TMT have been approved and marketed in China for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting) and EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy. Sac-TMT became the first domestic ADC with global intellectual property rights to be fully approved for marketing. It is also the world's first TROP2 ADC to be approved for marketing in a lung cancer indication. In addition, two new indication applications for sac-TMT for the treatment of adult patients with EGFR-mutant locally advanced or metastatic NSCLC who progressed after treatment with EGFR-TKI therapy and with unresectable locally advanced, metastatic HR+/HER2- BC who have received prior endocrine therapy and other systemic treatments in the advanced or metastatic setting were accepted by the CDE, and were included in the priority review and approval process. As of today, the Company has initiated 8 registrational clinical studies in China. MSD has initiated 14 ongoing Phase 3 global clinical studies of sac-TMT as a monotherapy or with pembrolizumab2 or other agents for several types of cancer. These studies are sponsored and led by MSD.
About Tagitanlimab (科泰莱®)Tagitanlimab is the first PD-L1 mAb globally to receive authorization for the first-line treatment of NPC. Previously, the NMPA has approved the marketing in China of tagitanlimab used in combination with cisplatin and gemcitabine for the first-line treatment of patients with R/M NPC and monotherapy for the treatment of patients with recurrent or metastatic NPC who have failed after prior 2L+ chemotherapy, respectively.
About Kelun-BiotechKelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical (002422.SZ), which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 3 projects have been approved for marketing, 1 project is in the NDA stage, and more than 10 projects are in the clinical stage. The company has established one of the world's leading proprietary ADC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit https://kelun-biotech.com/.
Media: klbio_pr@kelun.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/kelun-biotech-announces-breakthrough-therapy-designation-granted-for-sacituzumab-tirumotecan-sac-tmt-in-combination-with-tagitanlimab-in-china-for-certain-types-of-non-small-cell-lung-cancer-302478438.html
SOURCE Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Hong Kong Airlines Celebrates Inaugural Flight to Sydney
Offering Travellers More Direct Flight Options to Australia HONG KONG, June 21, 2025 /PRNewswire/ -- Hong Kong Airlines' inaugural flight between Hong Kong and Sydney, Australia, departed yesterday, making it the second local airline to operate this route and providing greater travel options for business, leisure, and transit passengers. To mark this new milestone in its network expansion, Hong Kong Airlines held celebratory events at both Hong Kong International Airport (HKIA) and Sydney Airport (SYD). Prior to departure, a launch ceremony was held at the boarding gate of the HKIA. The event was attended by distinguished guests, including Mr Jeff Sun, President of Hong Kong Airlines; Mr Ian McGraw from the Australian Consulate-General in Hong Kong; Ms Carmen Tam and Ms Vivien Yuen from Tourism Australia; Ms Jennifer Tung from Destination New South Wales; and Mr Ricky Chong from Airport Authority Hong Kong. The guests interacted with passengers and presented them with bespoke souvenirs to commemorate the historic occasion. During the event, Hong Kong Airlines President Mr Jeff Sun stated: "As a full-service local carrier, the launch of our Sydney service marks a significant step in our transformation to an international airline. Sydney is not only a popular destination for leisure and business travel but also one of Australia's most vital economic hubs. The expansion of the bilateral traffic rights agreement allows us to offer more choice to travellers in both cities, strengthening the connection between them." He added, "While Hong Kong Airlines may be a younger brand in the mature Australian market, we are endeavouring in our commitment to providing quality service. We operate this route with our Airbus A330 aircraft, featuring comfortable business and economy class cabins, and strive to deliver a passenger-centric in-flight experience through attentive service and fine dining for our long-haul customers." Sydney Airport CEO Mr Scott Charlton said: "We're proud to welcome Hong Kong Airlines to Sydney as our 52nd airline partner with its strong reputation for service excellence, efficiency and value. This inaugural service comes on the back of the first expansion in bilateral air traffic rights between Australia and Hong Kong in 19 years and we thank the Albanese Federal Government for its role in enabling this important agreement, which reflects the strength of our longstanding cultural and economic ties." NSW Minister for Jobs and Tourism Steve Kamper, said: "Hong Kong is a priority international market for NSW, with incoming travellers contributing substantially to the NSW visitor economy. The Minns Labor Government has made it very clear; we want to grow our visitor economy and the best way to do this is by increasing airline capacity and unlocking new international markets for NSW. We've set our sights on increasing the state's aviation capacity by 8.5 million seats, and this new Hong Kong route will complement other new routes we're securing as we work towards landing this goal." Mr Wang Yu, Consul General of People's Republic of China (Sydney), said: "As the second Hong Kong-based airline to operate the Hong Kong–Sydney route, Hong Kong Airlines not only provides a convenient new option for traveling between China and Australia, but also contributes to enhanced exchanges among students, tourists, business professionals and friends from all walks of life. This new service will strengthen Hong Kong and Sydney's role as vital gateways for the flow of people and goods, injecting fresh momentum into the economic and cultural ties between China and Australia. Its launch will also attract more international travelers to transit through Hong Kong or Sydney, further strengthening both cities' positions as global aviation hubs and creating new opportunities for trade and investment. Looking ahead, the Consulate-General of China in Sydney will continue to encourage and support airlines from both China and Australia in restoring or launching new routes based on the principle of mutual benefit and win-win cooperation. We believe that Hong Kong Airlines will continuously enhance its service quality and showcase a good corporate image." Also in attendance at the Sydney welcome ceremony were representatives from the Consulate-General of the People's Republic of China in Sydney, Destination NSW and the Hong Kong Economic and Trade Office (Sydney). Exclusive Lounge Access for Connecting Passengers To celebrate the launch of the new service, passengers travelling on this route and transit at Hong Kong for selected Hong Kong Airlines flights* to Vancouver, Bali, Tokyo, Osaka, Fukuoka, Shanghai (Pudong), Haikou, or Sanya, between 20 June and 31 October 2025, will receive complimentary access to the airline's flagship lounge "Club Autus" at Hong Kong International Airport. *Please click here for the relevant terms and conditions. Expanding Route Network The launch of the Sydney service indicates Hong Kong Airlines' overarching strategy for its network expansion. Coupled with the various significant destinations that have been inaugurated or reinstated since the start of the year, including Gold Coast in Australia, Vancouver in Canada, and Hulunbuir in Inner Mongolia of mainland China, the airline has cultivated a more extensive and diversified route map. This further underscores Hong Kong Airlines' commitment and contribution to the aviation industry's recovery and long-term development. In addition to the new routes, the Company also increased the frequency of services on multiple routes to cater to the summer travel demand. This includes the resumption of seasonal flights to the Maldives and an increase in flights to Da Nang to two per day. Additionally, flights to Shanghai Pudong will be increased to four per day, while services to Hangzhou and Nanjing will become twice day. The variety of flight times available throughout the day provides business, leisure, and transit passengers with the flexibility to plan their itineraries. The Company will launch another new service in July, providing passengers with more travel options. Hong Kong Airlines flight schedule* between Hong Kong and Sydney is as follows (All times local): Route Flight Number Departure Arrival Frequency HKG – SYD HX017 22:25 09:50+1 Daily SYD – HKG HX018 11:30 19:10 * Flight number and schedule may change without prior notice Please download high-resolution photos through this link. About Hong Kong Airlines Established in 2006, Hong Kong Airlines is a full-service airline firmly rooted in Hong Kong. The airline flies to over 30 destinations across the Asia Pacific and North America, and currently maintains interline and codeshares with multiple airline partners and ferry service providers. Hong Kong Airlines operates an all-Airbus fleet. It has been awarded the internationally acclaimed four-star rating from Skytrax since 2011. For more information, please visit or our social media channels on LinkedIn, Twitter, Instagram and Facebook. View original content to download multimedia: SOURCE Hong Kong Airlines Inicia sesión para acceder a tu portafolio
Yahoo
2 days ago
- Yahoo
ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC
Virtual webinar on June 23, 2025 at 8:00 am ET NEWTOWN SQUARE, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the Company will host a virtual investor event to discuss the firmonertinib clinical program for the treatment of EGFR PACC mutant non-small cell lung cancer (NSCLC) on June 23, 2025 at 8:00 am ET. To register for the event, please click here. About ArriVentArriVent is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. ArriVent seeks to utilize its team's deep drug development experience to maximize the potential of its lead development candidate, firmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization. About FirmonertinibFirmonertinib (formerly furmonertinib) is an oral, highly brain-penetrant, and broadly active mutation-selective epidermal growth factor receptor (EGFR) inhibitor active against both classical and uncommon EGFR mutations, including PACC and exon 20 insertion mutations. In March 2021, firmonertinib was approved in China for first-line advanced non-small-cell lung cancer (NSCLC) with EGFR exon 19 deletion or L858R mutations and for patients with previously treated locally advanced or metastatic NSCLC with EGFR T790M mutation, otherwise known as EGFR classical mutations. Firmonertinib was granted U.S. Food and Drug Administration Breakthrough Therapy Designation for the treatment of patients with previously untreated locally advanced or metastatic non-squamous NSCLC with EGFR exon 20 insertion mutations. Firmonertinib was also granted U.S. Food and Drug Administration Orphan Drug Designation for the treatment of non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutations or human epidermal growth factor receptor 2 (HER2) mutations or HER4 mutations. Firmonertinib is currently being studied in a global Phase 3 trial for first-line NSCLC patients with EGFR exon 20 insertion mutations (FURVENT; NCT05607550) and in a global Phase 1b study, which includes a cohort evaluating firmonertinib in patients with EGFR PACC mutations (FURTHER; NCT05364073). In addition, firmonertinib is also being studied in a clinical combination study targeting advanced or metastatic NSCLC patients with EGFR classical mutations, in partnership with Beijing InnoCare Pharma Tech Co., Ltd. About EGFR mutant NSCLCGlobally, lung cancer is the leading cause of cancer-related deaths among men and women. NSCLC is the predominant subtype of lung cancer, accounting for approximately 85% of all cases. Mutational activation of the EGFR is a frequent and early event in the development of NSCLC. EGFR mutations are divided into classical and uncommon. EGFR exon 20 insertion mutations are a group of uncommon EGFR mutations and constitute approximately 9% of all EGFR mutations. PACC mutations are another group of uncommon EGFR mutations and represent approximately 12% of all EGFR mutations. Patients with NSCLC whose tumors harbor uncommon EGFR mutations have significantly lower life expectancy with available therapies and represent an area of unmet medical need. Forward-Looking Statements This press release includes certain disclosures that contain 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans, activity of firmonertinib compared to available therapies, anticipated clinical milestones, including the top-line pivotal global Phase 3 data for firmonertinib in previously untreated NSCLC patients whose tumors contain EGFR exon 20 insertion mutations, expansion of firmonertinib into a pivotal trial for 1L EGFR PACC mutant NSCLC and the timing of the first patient enrolled in such study, participation in the global Phase 3 registrational study of firmonertinib in adjuvant uncommon mutant NSCLC, anticipated IND filings for ADC candidates, and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as 'anticipate,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' or the negative of these words or other similar terms or expressions. Forward-looking statements are based on ArriVent's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties that are described more fully in the section titled 'Risk Factors' in our annual report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Securities and Exchange Commission on March 3, 2025 and our other filings with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and ArriVent undertakes no duty to update such information except as required under applicable law. Contact:Joyce AllaireLifeSci Advisors, LLCjallaire@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Yahoo
China's Tai'an Mining Equipment Accelerates 'Going Global'
TAI'AN, China, June 20, 2025 /PRNewswire/ -- This is a report from the Shandong 0ffice of Hong Kong Business Daily. Recently, the "Vietnam China Shandong (Tai'an) Mining and Processing Technology Exhibition" was held in Vietnam to assist mining equipment enterprises in Tai'an City in exploring the Southeast Asian market. This exhibition is the first overseas self held exhibition of Tai'an's "Mount Taishan Brand Global Travel" campaign. A total of 21 mining equipment enterprises went to Vietnam to participate in this event, achieving an intended turnover of more than 50 million dollars, reaching more than 50 agency cooperation intentions, and achieving good trade results. This exhibition adopts a three in one model of "exhibition+trade docking+promotion", which provides a new platform for Sino Vietnamese mining equipment industry cooperation for enterprises. During the event, 126 buyers including Vietnam Coal Group were attracted to negotiate and connect. Tai'an Chuangdong New Material Technology Co., Ltd. signed a 1.2 million head order at the exhibition site, with an annual procurement scale of over 10 million US dollars, and simultaneously reached a memorandum of cooperation on new product technology. Shandong Ruiyu Mining Materials Processing Co., Ltd. seized the opportunity of cooperation in the raw material supply chain, opened up new growth points for subsequent business, successfully entered the largest support material supply chain system in Vietnam, and is expected to export over 2000 tons of goods annually. Tai'an Mount Taishan Huakun Machinery Co., Ltd. signed a technical cooperation memorandum with Yuemei Group on intelligent upgrading; Yongtai Mining Technology Co., Ltd. in Daiyue District, Tai'an City has obtained 5 customer process improvement needs, and 2 Vietnamese buyers plan to visit Thailand in June to inspect production lines and carry out deeper cooperation. The Tai'an Municipal Bureau of Commerce held a meeting to discuss the supply and demand of mining and processing technology equipment in Vietnam (Tai'an), and visited leading units in the Vietnamese coal mining industry such as the Vietnam Coal Mining Industry Group and the Vietnam Machinery Association. Next, Tai'an will continue to implement the activity of "Mount Taishan Brand Global Travel", organize and carry out key exhibitions such as "Russian International Construction and Construction Machinery Exhibition", "Sri Lanka Colombo Building Materials and Construction Machinery Exhibition", "Oman Construction Machinery and International Building Materials Exhibition", and help foreign trade enterprises in Tai'an expand emerging markets in Central Asia, the Middle East, Africa, etc. View original content: SOURCE Shandong Office of Hong Kong Business Daily
